Parcourir par sujet "PARATHYROID-HORMONE (1-34)"
Voici les éléments 1-2 de 2
-
Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial
(2008)Aims: We aimed to compare the effect of risedronate (RIS) and teriparatide (TPTD) (recombinant human parathyroid hormone 1-34) on bone turnover markers in women with postmenopausal osteoporosis. Methods: Forty-four Caucasian ... -
Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: A randomized, controlled trial
(2008)Risedronate and teriparatide have opposite actions on the osteoblast-osteoclast dipole and are expected to influence the RANK/RANKL/ osteoprotegerin (OPG) system. We aimed to evaluate changes in serum OPG and RANKL after ...